DeepMed Research

Rogel Cancer Center: University of Michigan

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1991-01-01

Employees: -

Market Cap: -

Website: http://www.rogelcancercenter.org

Clinical Trials

Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma

Phase 1

Active, not recruiting

Conditions: Recurrent Gliosarcoma
Newly Diagnosed Astrocytoma, Grade IV
Recurrent Glioblastoma
Newly Diagnosed Glioblastoma
Newly Diagnosed Gliosarcoma
Recurrent Astrocytoma, Grade IV

Interventions: Drug: Temozolomide
Radiation: Radiation Therapy
Drug: Mycophenolate Mofetil
Procedure: Re-resection (as part of standard of care)

First Posted Date: 2020-07-20

Last Posted Date: 2025-03-12

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 68

Registration Number: NCT04477200

Locations: 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States

Feasibility and Evaluation of a Self-care App to Enhance Purposeful Living

Not Applicable

Completed

Conditions: Ovarian Cancer

Interventions: Behavioral: Use of Purposeful app

First Posted Date: 2020-07-07

Last Posted Date: 2024-11-06

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 120

Registration Number: NCT04458168

Locations: 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States

Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma

Phase 1

Terminated

Conditions: Indolent Lymphoma

Interventions: Drug: Copanlisib
Drug: Nivolumab
Drug: Rituximab

First Posted Date: 2020-06-16

Last Posted Date: 2024-09-27

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 35

Registration Number: NCT04431635

Locations: 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸
University of Illinois Cancer Center, Chicago, Illinois, United States
🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

and more 2 locations

Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate Cancer

Not Applicable

Recruiting

Conditions: Prostate Cancer

Interventions: Other: Standard of care (askMUSIC score)
Device: Decipher
Device: Prolaris
Device: Oncotype Dx Genomic Prostate Score (GPS)

First Posted Date: 2020-05-21

Last Posted Date: 2024-04-18

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 900

Registration Number: NCT04396808

Locations: 🇺🇸
Spectrum Health Medical Group, Grand Rapids, Michigan, United States
🇺🇸
Western Michigan Urological Associates, Holland, Michigan, United States
🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States

and more 5 locations

Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer

Phase 2

Withdrawn

Conditions: Prostate Cancer

Interventions: Drug: Atezolizumab 1200 MG in 20 ML Injection
Drug: Abemaciclib 200 MG
Drug: Abemaciclib 150 MG

First Posted Date: 2020-02-17

Last Posted Date: 2020-07-15

Lead Sponsor: University of Michigan Rogel Cancer Center

Registration Number: NCT04272645

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸
Washington University - St. Louis, Saint Louis, Missouri, United States

and more 1 locations

Altering Lipids for Tolerance of Aromatase Inhibitor Therapy

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Dietary Supplement: Omega-3 fatty acid supplement

First Posted Date: 2020-02-13

Last Posted Date: 2024-02-29

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 77

Registration Number: NCT04268134

Locations: 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States

Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)

Phase 1

Completed

Conditions: Biliary Tract Cancer

Interventions: Drug: CPI 613
Drug: Cisplatin
Drug: Gemcitabine

First Posted Date: 2019-12-18

Last Posted Date: 2024-07-11

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 75

Registration Number: NCT04203160

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸
University Hospitals - Seidman Cancer Center, Cleveland, Ohio, United States
🇺🇸
Northwestern University -- Lurie Comprehensive Cancer Center, Chicago, Illinois, United States

and more 7 locations

A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer

Phase 1

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Drug: Niraparib
Drug: Leuprolide
Drug: Abiraterone Acetate
Radiation: Stereotactic body radiotherapy (SBRT)

First Posted Date: 2019-12-11

Last Posted Date: 2024-11-06

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 100

Registration Number: NCT04194554

Locations: 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
Cornell University, New York, New York, United States

and more 3 locations

Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy

Phase 2

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Daratumumab
Drug: Lenalidomide
Drug: Bortezomib
Drug: Dexamethasone

First Posted Date: 2019-10-25

Last Posted Date: 2024-10-09

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 57

Registration Number: NCT04140162

Locations: 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
🇺🇸
University of Texas Southwestern -- Simmons Comprehensive Cancer Center, Dallas, Texas, United States
🇺🇸
University of Rochester, Rochester, New York, United States

and more 1 locations

Health Information Technology System ("Roadmap 2.0") in the Context of Hematopoietic Cell Transplantation

Not Applicable

Completed

Conditions: Hematologic Diseases

Interventions: Other: Wearable activity sensor
Behavioral: Roadmap 2.0 information system
Other: Survey administration
Behavioral: Roadmap 2.0 information system with Positive Activities

First Posted Date: 2019-09-19

Last Posted Date: 2025-01-14

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 372

Registration Number: NCT04094844

Locations: 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States
🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy